| 國立臺灣大學 |
2012 |
Safety Analysis of FOLFOX4 Treatment in Colorectal Cancer Patients: A Comparison Between Two Asian Studies and Four Western Studies
|
Sugihara, Kenichi; Ohtsu, Atsushi; Shimada, Yasuhiro; Mizunuma, Nobuyuki; Lee, Po-Huang; de Gramont, Aimery; Goldberg, Richard M.; Rothenberg, Mace L.; Andre, Thierry; Brienza, Silvano; Gomi, Katsushige; 李伯皇 |
| 臺大學術典藏 |
2018-09-10T09:13:29Z |
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: A comparison between two Asian studies and four western studies
|
Sugihara, K. and Ohtsu, A. and Shimada, Y. and Mizunuma, N. and Lee, P.-H. and De Gramont, A. and Goldberg, R.M. and Rothenberg, M.L. and André, T. and Brienza, S. and Gomi, K.; PO-HUANG LEE |
| 臺大學術典藏 |
2020-11-19T03:19:35Z |
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: A comparison between two Asian studies and four western studies
|
Sugihara K.;Ohtsu A.;Shimada Y.;Mizunuma N.;Po-Huang Lee;De Gramont A.;Goldberg R.M.;Rothenberg M.L.;Andr? T.;Brienza S.;Gomi K.; Sugihara K.; Ohtsu A.; Shimada Y.; Mizunuma N.; PO-HUANG LEE; De Gramont A.; Goldberg R.M.; Rothenberg M.L.; Andr? T.; Brienza S.; Gomi K. |
| 淡江大學 |
2008-12 |
Safety Analysis of Level Crossing Surveillance Systems Using Fuzzy Petri Nets
|
Tao, Chi-chung; Lin,Tsung-chin |
| 臺大學術典藏 |
2022-09-06T08:33:56Z |
Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
|
Sheng, Wang-Huei; Wang, Chung-Cheng; Chu, Ching-Chi; Lin, Yueh-Juh; SUI-YUAN CHANG; Ieong, Si-Man; Chang, Shan-Chwen |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
| 國立成功大學 |
2021 |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque, A.;Chung, H.C.;Miguel, Miguel M.J.D.;Italiano, A.;MacHiels, J.-P.;Lin, C.-C.;Dhani, N.C.;Peeters, M.;Moreno, V.;Su, W.-C.;Chow, K.H.;Galvao, V.R.;Carlse, M.;Yu, D.;Szpurka, A.M.;Zhao, Y.;Schmidt, Schmidt S.L.;Gandhi, L.;Xu, Xu X.;Bang, Y.-J. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYnote-028 study
|
Hansen A.R.; Cheng J.D.; Thanigaimani P.; Saraf S.; CHIUN HSU; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study
|
Chiun Hsu;Lee S.-H.;Ejadi S.;Even C.;Cohen R.B.;Le Tourneau C.;Mehnert J.M.;Algazi A.;Van Brummelen E.M.J.;Saraf S.;Thanigaimani P.;Cheng J.D.;Hansen A.R.; Chiun Hsu; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Hansen A.R. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
|
Saraf S; Thanigaimani P; Cheng J.D; Keam B.; Mehnert J.M; Varga A; Brose M.S; Aggarwal R.R; Chia-Chi Lin; Prawira A; De Braud F; Tamura K; Doi T; Piha-Paul S.A; Gilbert J |
